

CPSI's SCN Cryoablation System Highlighted in New Medical Text

Chapter in *Multiscale Technologies for Cryomedicine* details the technologies and approaches used for cryoablation and features discussion of CPSI's patented next generation Supercritical Nitrogen cryoablation device.

July 6, 2016

OWEGO, NY - CPSI Biotech announced today the publication of the new medical text, *Multiscale Technologies for Cryomedicine – Implementation from Nano to Macroscale*, which includes a chapter authored by CPSI scientists. The chapter titled “Enhanced Cryoablative Methodologies” focuses on the various technologies, approaches and mechanisms involved in the use of cryoablation. In addition to technologies used today clinically, the chapter highlights several next generation technologies, including CPSI's supercritical nitrogen system (SCN), which has shown promise in advancing the application of cryoablation for the treatment of numerous cancers and cardiac arrhythmias.

The text, published by World Scientific Publishing Co, was co-edited by Dr. Xiaoming He (Ohio State University) and Dr. John Bischof (University of Minnesota) and is a compilation of works by renowned researchers working in the field of cryomedicine covering topic areas ranging from cryoablation of cancer to various aspects of cell cryopreservation. When asked about the book, Dr. John M. Baust (President, CPSI Biotech and lead author on CPSI's contribution) stated “Drs. He and Bischof should be congratulated for a superb job assembling this text. The book covers a broad array of hot topic areas in the field of Cryomedicine and should be highly valuable to a wide readership including clinicians and researchers alike.”

The chapter contribution by CPSI (Chapter 1: Enhanced Cryoablative Methodologies) details the current state of cryoablation in the treatment of cancer, its multi modal anticancer destructive nature as well as emerging technologies and approaches. The text covers the subject matter from the investigational and clinical perspectives. Discussion includes a focus on the SCN cryoablation technology developed by CPSI. Commenting on the chapter, Dr. Baust stated “this chapter not only provides an in-depth overview of the current state of cryoablation technologies, but goes deeper into discussion of several next generation cryo-based technologies and approaches which are aiming to provide advanced treatments for various cancers and heart arrhythmias. The development of these and other new technologies is critical given that many of today's approaches to treat cancer are being challenged by the molecular-based defensive and adaptive strategies possessed by cancer which enable it to defeat and/or avoid destruction. These new technologies are also being designed to enable more localized, minimally invasive treatment to reduce treatment side effects and cost.”

When asked specifically about the SCN technology Baust stated “the ability to quickly and controllably deliver an ultra-cold, highly powerful cryogenic insult to tissue targets in a

minimally invasive procedure has the potential to change how we treat many diseases. The SCN platform allows for the rapid and effective freezing of tissues in areas which have traditionally been challenging. Our belief is that the patented SCN technology will provide for a new cutting edge treatment option for the tens of millions of individuals in the US and worldwide battling cancer annually. The SCN technology has also shown tremendous promise in the treatment of other diseases, including cardiac arrhythmias.” More information on cryoablation and the SCN system can be found on CPSI’s website at www.CPSIBiotech.com

The text, initially published online in July, is timely in view of the growing interest in use of cryoablation for the treatment of cancer and can be accessed via the World Scientific Publishing Co website at <http://www.worldscientific.com/worldscibooks/10.1142/9870>

About CPSI Biotech - CPSI Biotech, a private, integrative bio/medtech greenhouse company, develops and designs life science research products and cryo-medical devices for applications in cancer, cardiovascular disease treatments and cell therapy bioprocessing. Ongoing R&D and business development activities continue to produce innovative technologies, devices and intellectual property for commercialization, licensing or sales in support of diverse clinical and research applications. By leveraging the innovation, flexibility and R&D strengths of CPSI in combination with the development, commercialization, manufacturing and clinical expertise of partnering organizations, rapid and efficient product development is attainable.

Disclosure Notice: The information contained in this release is as of July 6, 2016. CPSI assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. CPSI’s technologies do not have regulatory clearance for commercial sale and are currently intended for “Research Use Only”.

With the exception of the historical information contained in this release, this release contains materials and statements related to future business, financial performance, future events and/or developments involving CPSI which constitute forward-looking statements. The matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to, CPSI’s ability to develop and market new products, to retain and attract key employees, to obtain regulatory clearances and approvals for its products, to effectively react to other risks and uncertainties, such as fluctuation of quarterly financial results, contract and grants acquisition, reliance on third party manufacturers and suppliers, litigation or other proceedings, economic, competitive, governmental impacts, whether pending patents will be granted or defensible, validity of intellectual property and patents, the ability to license patents, the ability to commercialize developmental products, competition from existing and new products and procedures and CPSI’s ability to raise the capital that is required to accomplish the foregoing.

Contacts

CPSI Biotech Contact:

John M Baust, Ph.D., President & Lead Scientist

Kristi Snyder, Ph.D., Director of Operations

Tel: 607-687-8701 Email: contact@cpsibiotech.com